Knowledge, attitudes, and factors influencing clinical trial participation among breast cancer patients in Brazil: The LACOG 1123 (ASTRAL) study.
Abstract
e23209 Background: Despite Brazil’s growing participation in clinical cancer research, data on knowledge, attitudes, and factors influencing clinical trial participation remain limited. The LACOG 1123 (ASTRAL) study evaluated these aspects among Brazilian patients with breast cancer (BC). Methods: Patients ≥18 years diagnosed with stage I-IV BC within the previous five years and receiving active treatment or having completed treatment within two years were invited by their treating physicians to complete an electronic survey. The questionnaire included sociodemographic and clinical characteristics, as well as questions related to clinical research adapted from previously published surveys. Results: A total of 350 responses were received from all regions of Brazil. Most physicians worked both in private and public setting (52%). Median age was 49.0 years (IQR 42-60), 54.6% were white, and 85.3% had private health insurance. The majority had initial disease (32.5%) and 89.1% were receiving active treatment. Regarding previous knowledge on clinical research, 63.1% reported having heard about clinical trials, most of them learned through some kind of media (68%); however, 65.5% were unaware of the existence of research centers at their treatment sites. Only 13.1% had ever been invited to participate in a clinical trial. The main motivation to participate was contributing to science (38.8%), followed by contributing to the hospital and care team (25.1%). Physicians’ opinions were reported to play a central role in decision-making by 76.2% of participants, and 74.5% reported that refusing participation would not compromise the quality of care. Regarding perceptions of clinical research, 79.1% agreed that clinical trials benefit patients and society, 67.2% reported willingness to participate if invited, and 61.6% would encourage relatives or friends to participate. Regarding concerns to participation, 18% reported fear of being treated as a “guinea pig,” whereas 39.4% reported no fear of participating. Conclusions: Brazilian BC patients demonstrate strong altruistic and pro-science attitudes, with high willingness to participate in and encourage clinical trial enrollment. Although overall awareness levels were relatively high, access to clinical trials remains substantially lower than that reported in high-income settings. Moreover, the study population was skewed toward higher socioeconomic status, despite balanced representation of physicians from private and public institutions, likely overestimating levels of research awareness. Persistently low invitation rates likely reflect not only limited physician engagement, but also restricted trial availability and insufficient awareness of ongoing studies among care teams, highlighting key opportunities to expand equitable access and strengthen patient confidence in clinical research.
Article Details
Journal Info
Journal of Clinical Oncology
Lippincott Williams & Wilkins
Authors (20)
Gisah Guilgen
Instituto do Câncer e Transplante de Curitiba (ICTr), Curitiba, Brazil and Grupo Brasileiro de Estudos em Câncer de Mama (GBECAM), Porto Alegre, Brazil
Debora De Melo Gagliato
Hospital Beneficência Portuguesa, São Paulo, Brazil
Angelica Nogueira Rodrigues
Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Brazil and Oncoclínicas do Brasil, Belo Horizonte, Brazil
Gustavo Werutsky
Latin American Cooperative Oncology Group, Porto Alegre, Brazil
Daniela Dornelles Rosa
Laura Testa
Instituto D’Or de Pesquisa e Ensino (IDOR), São Paulo, Brazil
Romualdo Barroso-Sousa
Brasilia Hospital, Rede Américas, Brasilia, Brazil
Renata Colombo Bonadio
Instituto D’Or de Pesquisa e Ensino (IDOR), São Paulo, Brazil
José Márcio Barros de Figueiredo
Instituto do Câncer Brasil de Ensino e Pesquisa, Taubaté, Brazil
Daniele Assad Suzuki
Hospital Sírio-Libanês, Brasília, Brazil
Daniela Oliveira
Santa Casa de Misericórdia da Bahia - Hospital Santa Izabel, Salvador, Brazil and Núcleo de Oncologia da Bahia (NOB) – Grupo Oncoclínicas, Salvador, Brazil
Tomas Reinert
Centro de Oncologia do Hospital Nora Teixeira - Santa Casa de Porto Alegre, Porto Alegre, Brazil and Grupo Brasileiro de Estudos em Câncer de Mama (GBECAM), Porto Alegre, Brazil
Poliana Albuquerque Signorini
Fernanda Madasi Pinheiro
Instituto D’Or de Pesquisa e Ensino (IDOR), Rio De Janeiro, Brazil
Maria Eduarda Meyer
Grupo Elora, Florianópolis, Brazil
Barbara Winter
Instituto do Câncer e Transplante de Curitiba (ICTr), Curitiba, Brazil
Juliana Giacomazzi
Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil
Vitoria Garcia
Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil
Gustavo Gössling
Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil
Luciana Castro Landeiro
Oncoclínicas&Co, Salvador, Brazil and Grupo Brasileiro de Estudos em Câncer de Mama (GBECAM), Salvador, Brazil